1.96 USD
0 (0%)
1.96 USD
0 (0%)
Overall CLSN gets a fundamental rating of 1 out of 10. We evaluated CLSN against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of CLSN have multiple concerns. CLSN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- CLSN had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.03% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Operating Margin and Gross Margin are not available for CLSN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -5229.82% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CLSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CLSN has less shares outstanding
- The debt/assets ratio for CLSN has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -7.47, we must say that CLSN is in the distress zone and has some risk of bankruptcy.
- A Debt/Equity ratio of 0.13 indicates that CLSN is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.47 |
ROIC/WACCN/A
WACC10.77%
2.3 Liquidity
- CLSN has a Current Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
- CLSN has a Quick Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.52 | ||
| Quick Ratio | 6.52 |
3. Growth
3.1 Past
- CLSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.02%.
- The Revenue has decreased by -2.91% in the past year.
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.33%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Sales Q2Q%0%
3.2 Future
- The Earnings Per Share is expected to grow by 5.59% on average over the next years.
- The Revenue is expected to decrease by -22.71% on average over the next years. This is quite bad
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- CLSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLSN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.03 |
4.3 Compensation for Growth
- CLSN's earnings are expected to grow with 14.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.03%
EPS Next 3Y14.57%
5. Dividend
5.1 Amount
- No dividends for CLSN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CELSION CORP / CLSN FAQ
What is the fundamental rating for CLSN stock?
ChartMill assigns a fundamental rating of 2 / 10 to CLSN.
Can you provide the valuation status for CELSION CORP?
ChartMill assigns a valuation rating of 3 / 10 to CELSION CORP (CLSN). This can be considered as Overvalued.
What is the profitability of CLSN stock?
CELSION CORP (CLSN) has a profitability rating of 1 / 10.